Article

FDA Approves Nasal Spray Treatment for Migraine

Author(s):

The FDA has approved sumatriptan nasal spray (Tosymra, Promius Pharma) for the acute treatment of migraine with or without aura in adults.

The FDA has approved sumatriptan nasal spray (Tosymra, Promius Pharma) for the acute treatment of migraine with or without aura in adults.

The nasal spray is formulated using a proprietary novel excipient known as Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action, according to Anil Namboodiripad, PhD, president of Promius Pharma.

Due to its formulation, the spray results in a rapid onset of action. Approximately 26% to 40% of migraine patients are not optimally controlled with their current treatment, according to independent research. A need for reliable and efficacious treatment options continues for patients who suffer from the debilitating and disruptive effects of migraine.

A version of this article was originally published by our sister publication Md Magazine. For more information, visit MdMag.com.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com